EA201492271A1 - Соединения хроманов - Google Patents

Соединения хроманов

Info

Publication number
EA201492271A1
EA201492271A1 EA201492271A EA201492271A EA201492271A1 EA 201492271 A1 EA201492271 A1 EA 201492271A1 EA 201492271 A EA201492271 A EA 201492271A EA 201492271 A EA201492271 A EA 201492271A EA 201492271 A1 EA201492271 A1 EA 201492271A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
treatment
pharmaceutical composition
alzheimer
chroman
Prior art date
Application number
EA201492271A
Other languages
English (en)
Other versions
EA026380B1 (ru
Inventor
Ресуке Мунаката
Макото Иноуе
Хироаки Томинага
Синго Ямасаки
Ясухиро Сиина
Кийохиро Самидзу
Хисао Хамагути
Линь Хун
Original Assignee
Коментис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Коментис, Инк. filed Critical Коментис, Инк.
Publication of EA201492271A1 publication Critical patent/EA201492271A1/ru
Publication of EA026380B1 publication Critical patent/EA026380B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к соединению, которое полезно в качестве активного ингредиента фармацевтической композиции, в частности фармацевтической композиции для профилактики или лечения состояний, связанных с и/или опосредованных активностью β-секретазы, гидролизом участка расщепления β-секретазы белка-предшественника амилоида и/или накоплением белка β-амилоида, включая фармацевтические композиции для профилактики или лечения, включая без ограничения глаукому, MCI (легкое когнитивное нарушение) или болезнь Альцгеймера, главным образом болезнь Альцгеймера.
EA201492271A 2012-05-30 2013-05-29 Соединения хроманов EA026380B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261653321P 2012-05-30 2012-05-30
US201361782038P 2013-03-14 2013-03-14
PCT/US2013/043016 WO2013181202A2 (en) 2012-05-30 2013-05-29 Chromane compounds

Publications (2)

Publication Number Publication Date
EA201492271A1 true EA201492271A1 (ru) 2015-10-30
EA026380B1 EA026380B1 (ru) 2017-04-28

Family

ID=49674034

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492271A EA026380B1 (ru) 2012-05-30 2013-05-29 Соединения хроманов

Country Status (15)

Country Link
US (2) US8975415B2 (ru)
EP (1) EP2854797A4 (ru)
JP (1) JP2015518048A (ru)
KR (1) KR20150023536A (ru)
CN (1) CN104394862A (ru)
AR (1) AR091203A1 (ru)
AU (1) AU2013267555A1 (ru)
BR (1) BR112014029597A2 (ru)
CA (1) CA2873678A1 (ru)
EA (1) EA026380B1 (ru)
HK (1) HK1208817A1 (ru)
MX (1) MX2014014066A (ru)
SG (1) SG11201407796YA (ru)
TW (1) TW201408672A (ru)
WO (1) WO2013181202A2 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013267555A1 (en) 2012-05-30 2014-12-04 Comentis, Inc. Chromane compounds
UY36347A (es) * 2014-10-07 2016-04-01 Astrazeneca Ab Compuestos y su uso como inhibidores de bace
CN110790753B (zh) * 2019-11-18 2023-04-07 上海医药工业研究院 艾拉普林对甲苯磺酸盐、其制备方法和应用
CN110818694B (zh) * 2019-11-18 2023-04-21 上海医药工业研究院有限公司 艾拉普林中间体及其应用
CN110713483B (zh) * 2019-11-18 2023-04-07 上海医药工业研究院 艾拉普林中间体及艾拉普林的制备方法
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
US20040121947A1 (en) 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
CA2464736A1 (en) 2001-10-23 2003-05-15 Oklahoma Medical Research Foundation Beta-secretase inhibitors and methods of use
MXPA06006730A (es) 2003-12-15 2006-08-31 Schering Corp Inhibidores de aspartil proteasa heterociclicos.
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
EP2318416B1 (en) 2008-07-28 2013-09-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
WO2010013302A1 (ja) * 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
JP5444240B2 (ja) * 2008-07-28 2014-03-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
US8450308B2 (en) * 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US8426447B2 (en) * 2008-09-11 2013-04-23 Amgen Inc. Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use
PT2406240E (pt) 2009-03-13 2016-02-24 Boehringer Ingelheim Int Inibidores de beta-secretase
US8461160B2 (en) 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
WO2011072064A1 (en) * 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
EP2539322B1 (en) * 2010-02-24 2014-01-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
JP2013522305A (ja) * 2010-03-15 2013-06-13 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのスピロ−四環式環化合物
JP5584352B2 (ja) * 2010-03-15 2014-09-03 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
AR080865A1 (es) * 2010-03-31 2012-05-16 Array Biopharma Inc Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2012040641A2 (en) 2010-09-24 2012-03-29 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
TW201300380A (zh) 2010-10-19 2013-01-01 Comentis Inc 抑制β-分泌酶活性之噁二唑化合物及其使用方法
AR083953A1 (es) 2010-11-22 2013-04-10 Array Biopharma Inc Compuestos para tratar enfermedades neurodegenerativas
US8957083B2 (en) 2010-11-23 2015-02-17 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
WO2012109165A1 (en) 2011-02-07 2012-08-16 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
US9079919B2 (en) 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
JP2014526560A (ja) 2011-09-21 2014-10-06 アムジエン・インコーポレーテツド β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法
US9650336B2 (en) 2011-10-10 2017-05-16 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
AU2013267555A1 (en) 2012-05-30 2014-12-04 Comentis, Inc. Chromane compounds
EP2669286A1 (en) 2012-05-31 2013-12-04 Ares Trading S.A. Spiro tetrahydro-benzothiophen derivatives useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
TW201408672A (zh) 2014-03-01
US9242973B2 (en) 2016-01-26
EP2854797A2 (en) 2015-04-08
MX2014014066A (es) 2015-03-19
JP2015518048A (ja) 2015-06-25
EP2854797A4 (en) 2016-01-13
WO2013181202A2 (en) 2013-12-05
WO2013181202A3 (en) 2014-01-30
KR20150023536A (ko) 2015-03-05
BR112014029597A2 (pt) 2017-11-07
SG11201407796YA (en) 2014-12-30
EA026380B1 (ru) 2017-04-28
US8975415B2 (en) 2015-03-10
CA2873678A1 (en) 2013-12-05
US20150225386A1 (en) 2015-08-13
US20140179695A1 (en) 2014-06-26
AU2013267555A1 (en) 2014-12-04
AR091203A1 (es) 2015-01-21
HK1208817A1 (en) 2016-03-18
CN104394862A (zh) 2015-03-04

Similar Documents

Publication Publication Date Title
EA201492271A1 (ru) Соединения хроманов
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201270824A1 (ru) Соединения для уменьшения продукции бета-амилоида
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201892339A3 (ru) Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201590353A1 (ru) Способы лечения болезни альцгеймера и фармацевтические композиции
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201391561A1 (ru) Новые соединения-модуляторы gpr-119
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201892050A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
EA201101479A1 (ru) Новые p2x7r антагонисты и их применение
EA201890859A1 (ru) Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU